Synthetic Biologics Inc.is developing an oral, statin-based candidate for chronic use that it thinks can get at the root cause of constipation-predominant irritable bowel syndrome – the overgrowth of a particular type of intestinal bacteria called methanogens.
During an investor briefing on Sept. 16, the company said that it has developed a plan that should enable it to have Phase II data by Autumn 2015 for SYN-010,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?